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Abstract
MicroRNAs (miRNAs) are a class of small non-coding RNAs which function in gene regulation with an important
role in cell proliferation, maturation, and activity. The regulatory role of these small RNA molecules has recently
begun to be explored in ovarian cells, uncovering their influence on gonadal development, steroidogenesis,
apoptosis, ovulation, and corpus luteum development. This emerging area of research has extended and reshaped
our understanding on how ovarian function is regulated. Here, we review the current understanding of miRNA
biogenesis, the role and mechanism that miRNAs play in post-transcriptional gene expression regulation, and
specifically the current evidence of miRNA involvement in ovarian development and function. Future
comprehensive understanding of the role of miRNAs in the ovary in both physiological and pathological
conditions may offer new treatment strategies for infertility and other ovarian disorders.
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MicroRNAs (miRNAs) are small (19-25 bp) RNAs that
diversely regulate gene expression through their
decrease of messenger RNA (mRNA) stability or transla-
tion [1-3]. The functions of these non-coding RNAs,
until recently, have been relatively unknown, and are
emerging as important regulators controlling diverse
physiological and pathological processes including cell
division, differentiation, migration and apoptosis [2,3].
Ovarian development involves proliferation and differen-
tiation of germ cells and somatic cells. The correct com-
pletion of these processes is dependent on the
coordinated expression of genes in a spatially and tem-
porally specific manner. Consequently, gene expression
is highly regulated and controlled at both the transcrip-
tional and translational level. It is thus conceivable that
miRNAs also play an important role in ovarian develop-
ment. Here we review some of the recent findings on
the potential roles of miRNA in ovarian functions.
MicroRNA biosynthesis, function and degradation
The genes that encode miRNAs, which comprise a class
of naturally occurring, small non-coding RNAs, are gen-
erally transcribed by RNA polymerase II, processed into
short hairpin RNAs by the enzyme Drosha and its
RNA-binding cofactor DiGeorge syndrome critical
region gene 8 (DGCR8), as shown in Figure 1 [4-7].
Within the nucleus, these two proteins convert primary
miRNA (pri-miRNA) to ~70-100 base precursor-miRNA
( p r e - m i R N A )t h a tc o n t a i nac h a racteristic hairpin loop.
The pre-miRNAs are exported from the nucleus to the
cytoplasm, and further processed by another enzyme,
Dicer (encoded by Dicer1), giving rise to mature miR-
NAs. These are then transferred to Argonaute proteins,
members of the argonaute (Ago) protein family, in an
Argonaute-containing RNA Induced Silencing Complex
(RISC) and elicit their effects by binding within the 3’-
untranslated region (3’ UTR) of target mRNAs [8].
There are some special cases in which the miRNA do
not undergo the regular processing steps during bio-
synthesis. Mirtrons are a subset of miRNAs which uti-
lize an alternative pathway for miRNA biogenesis [9].
These miRNAs are located within short introns, and
once splicing is complete, a debranching enzyme gener-
ates the pre-miRNA-like hairpin which can then be
exported from the nucleus to the cytoplasm. Generally,
mirtrons compose only a small percentage of genomi-
cally encoded miRNAs, as the sequences of mirtrons are
not evolutionarily conserved [10]. It was proposed that
the conversion of a short intron into a mirtron may
represent an evolutionary opportunistic strategy for the
development of new gene regulating RNAs [11]. Once
the mature miRNA duplex is produced, it usually loses
one of its strands (the complementary strand*) as the
presence of structure imperfections within this duplex
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from the RISC Loading Complex (RLC). The mature
miRNA strand is then loaded onto the Argonaute-
containing RISC (miRISC) which facilitates gene silen-
cing [12]. Recognition is thought to mainly involve base
pairing of miRNA nucleotides 2-8, representing the seed
sequence [13]. The miRISC then uses the miRNA strand
as a guide to search for mRNAs in which the 3’UTR is
complementary to the miRISC seed sequence. It has
been estimated that 30-90% of messenger RNAs may be
subjected to miRNA regulation, and individual miRNAs
are predicted to target up to several hundred genes
[14-16]. Many highly regulated mRNAs contain multiple
miRNA binding sites, often targeted by different miR-
NAs, which may enhance the effectiveness of regulation
[17]. MiRNAs exert their effect by negatively regulating
gene expression through one of two mechanisms, i.e.,
mRNA degradation or translational suppression. The
mechanism by which the miRNA proceeds is dependent
on the complementarity between the miRNA and its
mRNA target [18-20]. A high level of complementarity
corresponds to the degradation of the target mRNA via
the RNA-mediated interference (RNAi) pathway. When
there is inadequate complementarity, miRNAs bind
to the 3’UTR of the target mRNAs and translational
suppression occurs through miRISC. Plants more
commonly use the first mechanism while animals more
often utilize the second [2]. It was proposed that there
is a competition between miRISC and eIF4E for associa-
tion with the mRNA 5’ cap structure. eIF4E is a eukar-
yotic translation initiation factor which binds to the 7-
methyl guanosine cap structure present at the 5’ UTR of
cellular mRNA, consequently delivering it to the eIF4E
translation initiation complex [21]. MiRNA can repress
translation by interfering with the ability of the 7-methyl
guanosine cap structure at the 5’ end of mRNA to
engage the translation initiation complex, which is nor-
mally mediated by eIF4E [22]. Evidence of the competi-
tion between miRISC and eIF4E is supported by
experiments in which the eIF4E translation initiation
complex is artificially tethered to mRNA, resulting in
resistance of translational repression by miRNAs [22].
This cap-dependent mechanism of translation inhibition
is also supported by experiments indicating that some
mRNAs lacking the 7-methyl guanosine cap structure
are not able to be repressed by miRNAs [22]. If miRISC
does in fact compete with eIF4E then it would be pre-
dicted that providing excess eIF4E would alleviate
repression. This is in fact the case when purified eIF4E
is added to the system [23]. Ago2 proteins play a role in
miRNA regulation of gene expression as the Mid
domain of Ago2 has been proposed to resemble eIF4E,
Figure 1 Model of microRNA (miRNA) biogensis/transportation/function. In the nucleus, miRNA are transcribed by RNA polymerase II into
single strand RNA, which folds into a double stranded primary miRNA (pri-miRNA). Pri-miRNA are cleaved by Drosha yielding the precursor
miRNA (pre-miRNA). Pre-miRNA are then translocated from the nucleus via exportin 5 to the cytoplasm. Once in the cytoplasm pre-miRNA are
further cleaved by the RNase III endonuclease Dicer into a double stranded miRNA. Only one strand of the duplex is stably associated with the
miRISC complex. The miRNA strand is usually favoured more than the miRISC* strand, although there are exceptions. The double stranded
miRNA then separates into two single strands, one strand is then degraded and the other is incorporated into a complex with argonaute
proteins, forming the RNA induced silencing complex (RISC). RISC then binds to target mRNA causing translational repression or degradation.
Adapted and modified from [7].
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adopting equivalent positions to the eIF4E tryptophans.
Mutation of the phenylalanines impairs the ability of
Ago2 to repress translation [24]. In addition, miRNAs
may also increase translation of specific mRNAs in a
manner dependent on the cell cycle [25], and a large
number of miRNAs may be expressed in a tissue-speci-
fic manner [26].
Small RNA in the ovary
The ovary performs numerous roles critical for oocyte
development and ovulation. Within the ovary, granulosa
cells are an important site for estrogen production for
local use as well as providing endocrine signalling to
other tissues [27]. The somatic cells of the ovary act to
support the growth and development of the oocyte in
preparation for the surge of luteinizing hormone (LH)
which elicits a physiological response leading to ovula-
tion. This response includes promoting meiosis, steroi-
dogenesis, follicular development, cumulus cell
expansion, luteinization, and progesterone production,
ultimately promoting oocyte maturation [28,29].
The role of small RNA in the ovary is indicated by the
fact that knockout of Dicer, the ribonuclease III which
processes pre-small RNA to mature functional small
RNA in the ovary resulted in the dysfunction of follicu-
logenesis, oocyte maturation, ovulation and infertility
[30-34]. Piwi interacting RNAs (piRNAs), miRNA, and
small interfering RNA (siRNA) are the major small
RNAs present in the ovary. PiRNA is primarily
expressed and functions in the germ cell [35]. Endogen-
ous siRNA utilize the well-known RNA interference
pathway to regulate gene expression [36,37]. In this reg-
ulatory system, endogenous double stranded RNAs
(dsRNAs) are thought to derive from pseudogenes that
encode a complementary mRNA allowing for formation
of dsRNA templates, Dicer cleavage of the dsRNA then
generates endogenous siRNAs [36,37]. With respect to
endogenous siRNAs, they have been identified to play a
role in oocytes [36,37]. Knockout of DGCR8, which
should specifically block the miRNA pathway, and leave
the endogenous siRNA pathway intact helps to distin-
guish the effects of these closely related classes of RNA
species (i.e., miRNA and siRNA) [38]. Targeted deletion
of oocyte DGCR8, an enzyme specific for miRNA bio-
synthesis, had no significant adverse effect on matura-
tion of oocytes [39], indicating that the role of miRNA
synthesized via this pathway in the oocyte is limited.
However, miRNA could also be generated by direct
transcription of short hairpin RNAs and mirtrons (i.e.,
pre-miRNA that arise from intron excision) which short
circuit the standard miRNA biogenesis process by elimi-
nating the need for Drosha/DGCR8 mediated cleavage
[11,40]. It is thus still unknown if miRNAs generated via
these pathways play a role in oocyte growth and matura-
tion. Nevertheless, increasing evidence support the
notion that influence of miRNA on ovarian function pri-
marily occurs through their actions on ovarian somatic
cells such as granulosa cells. In order to determine the
possible involvement of miRNAs in reproductive tissues,
expression levels have been measured indicating the pre-
sence of large numbers of miRNA within the ovary.
However, the functional importance of individual
miRNA and the identity of their mRNA targets are now
beginning to be discovered.
MicroRNA in gonadal and early embryo development
Fetal gonadal development involves coordinated expres-
sion of thousands of genes, and it is conceivable that
miRNAs are involved in the regulation of these genes
during fetal development. In a recent study by Torley et
al. (2011), key genes involved in fetal ovarian develop-
ment were examined as potential targets of miRNA reg-
ulation [41]. This study provides evidence that miR-22
is up-regulated during testicular development and
down-regulated during fetal ovarian development, corre-
lating to increased estrogen receptor 1 (ESR1) expres-
sion levels during fetal ovarian development. This study
suggests there is a repressive effect by miR-22 on estro-
gen signalling as a result of its influence on ESR1, indi-
cating Sertoli cell development requires suppression of
estrogen during testicular development [41].
Bannister et al.(2009), has shown that miRNAs are
expressed in a sexually dimorphic manner in embryonic
chicken gonads during sexual differentiation [42]. To
further test the hypothesis that up-regulation of micro-
RNA 202* (miR-202*) is specifically associated with tes-
ticular differentiation, estrogen modulation was used to
feminize male (ZZ) gonads and masculinize female
(ZW) gonads in order to study the association between
male-biased miR-202* expression and gonadal sex differ-
entiation. In ovo injection of estradiol-17 beta resulted
in feminization of male gonads which was accompanied
by a reduction in miR-202* expression levels, similar to
the female phenotype. When estrogen synthesis was
blocked, female gonads were masculinized, which is
associated with increased miR-202* and down-regulation
of the ovary specific Forkhead box L2 (FOXL2) gene,
and up-regulation of testis associated genes; double sex
and mab3 related transcription factor 1 (DMRT1) and
SRY (sex determining region Y) box 9 (SOX9) genes.
These results suggest that miR-202* may be involved in
regulating gonadal development [43].
Newborn ovary homebox gene (NOBOX) is a tran-
scription factor and NOBOX mRNA and protein are
expressed in oocytes throughout folliculogenesis [44].
T h ei m p o r t a n c eo ft h i sg e n ei se v i d e n ta sN O B O X
knockout mice are infertile, and mutations in the
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ovarian failure (POF), suggesting the essential role of
NOBOX in folliculogenesis. As a potential miRNA
recognition element (MRE) for miR-196a was identified
in the 3’UTR of bovine NOBOX mRNA, a previous
study investigated the possible regulatory effects of miR-
196a on NOBOX expression [44]. During early embryo-
genesis, miR-196a steadily increases while NOBOX gra-
dually decreases. This inverse relationship supports the
proposed role of miR-196a as a regulator of NOBOX
during early embryogenesis. To confirm the mechanism
of this regulation, HeLa cell transfection studies and
Western blot assays were conducted in which a signifi-
cant inhibition of NOBOX expression was observed in
HeLa cells expressing both NOBOX and miR-196a, in
comparison to cells transfected with NOBOX alone. To
determine the ability of miR-196a to regulate endogen-
ous NOBOX expression, bovine early embryos were
microinjected with miR-196a which resulted in reduced
NOBOX mRNA and protein levels compared to nega-
tive control embryos, suggesting miRNA not only inhibit
translation, but may also induce clearance of target
mRNA [44].
Recent studies have also illustrated the importance of
maternally inherited miRNAs in the oocyte for early
embryonic development. One such maternal effect gene
is Nucleoplasm 2 (NPM2), which is an oocyte specific
nuclear protein essential for maternal and paternal DNA
remodelling during early embryonic development, and is
positively associated with oocyte developmental compe-
tence [45]. An inverse correlation was reported between
miR-181a and NPM2 during early embryogenesis. Co-
expression studies with NPM2 and miR-181a indicated
a reduced expression of NPM2 protein in miR-181a-
expressing cells compared to control cells without miR-
181a, suggesting that translation of NPM2 is repressed
by miR-181a and a key role of this miRNA in regulating
early embryonic development [45].
Hormonal regulation of microRNA expression in the ovary
Recent evidence supports the role of luteinizing hor-
mone (LH)/human chorionic gonadotropin (hCG) in the
regulation of miRNA expression [46]. Ovarian granulosa
cells are likely an important target for LH-regulated,
miRNA-mediated changes in gene expression during
LH-induced luteinization. Following LH/hCG stimula-
tion in the ovarian cells, miR-132 and miR-212 which
share the same seed sequence were found to be highly
up-regulated, suggesting their potential role in ovarian
response to LH. It is suggested that miR-132 and miR-
212 play an important role as post-transcriptional regu-
lators in granulosa cells, as computational analysis has
identified 77 putative mRNA as potential targets of
miR-212, and miR-132 in granulosa cells [46]. C-
terminal binding protein 1 (CTBP1) is a known target of
miR-132, and the gene product acts as a co-repressor of
nuclear receptor genes. Interestingly, knockdown of
both miR-212 and miR-132 resulted in decreased pro-
tein levels of CTBP1 but with no change in mRNA
levels [46]. Further studies to determine how these miR-
NAs cause these changes in CTBP1 expression would
be useful to establish the precise relationship. These
results suggest that miRNA may play a key role in tun-
ing the gene expression cascade to allow for ovulation
and the differentiation of luteal cells.
Follicle Stimulating Hormone (FSH) controls the
development of granulosa cells during folliculogenesis
by stimulating their proliferation and differentiation
[47]. In particular, FSH regulates expression of several
granulosa cell genes during FSH induced steroidogen-
esis. Examples of these FSH regulated genes include
insulin like growth factor binding protein 3 (IGFBP3),
steroidogenic acute regulatory protein (StAR), as well as
numerous bone morphogenetic proteins (BMPs) [48-51].
The primary trigger of immature preantral follicle devel-
opment into preovulatory follicles is FSH. A study
reported that after 12 hours of FSH exposure, 17 miR-
NAs were up regulated and 14 miRNAs were down
regulated. In this same study progesterone levels in the
medium were up regulated by FSH at 12 hours [47],
s u g g e s t i n gt h a tm i R N A sm a yp l a yar o l em e d i a t i n g
changes in gene expression and thus hormone produc-
tion in granulosa cells following FSH exposure. Future
molecular analysis would be important for confirming
the specific binding between miRNA and the 3’UTR of
potential target genes to better understand the role of
miRNA in the phenotypic changes occurring following
FSH exposure. Furthermore, the association between the
proposed miRNAs and potential target genes regulating
progesterone production are to be verified. The same
study also revealed a bi-phase regulation of miRNAs by
FSH. A significant decrease in the expression levels of
miR-29a and miR-30d during the first 12 hours post
FSH exposure was observed [47]. However, FSH induced
a 2 and 3 fold increase in the expression of miR-29a and
miR-30d at 48 hours post-FSH exposure, respectively
[47]. This finding suggests that these two miRNAs could
be involved in the fine tuning of FSH mediated granu-
losa cell function. In addition, it was also demonstrated
that granulosa cells collected immediately before and 4
h after the ovulatory surge of LH/hCG exhibit differen-
tial miRNA expression patterns [46], suggesting a role
in ovulation. Interestingly, a lack of miR17-5p and let7b,
resulted in corpus luteum insufficiency and infertility in
mice, and the phenotype was partially reversed by injec-
tion of miR17-5p and let7b into the ovaries in the mice
[32], indicating the role of these miRNAs in corpus
luteum formation.
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Using a large-scale platform approach, it was recently
shown that 51 microRNAs have suppressive effects on
estradiol production [52]. MiRNAs shown to suppress
the release of progesterone, androgens, and estrogens
include miR-108, miR-135, miR-146, miR-19a, miR-20,
miR-27, miR-28, miR-29, miR-125b, miR-126, miR-137,
miR-184, miR-31, miR-105, miR-128, miR-129, miR-132,
miR-140, and miR-188. It was hypothesized that these
miRNAs act as physiological suppressors of general
secretory activity [52]. In addition, over-expression of
miR-24, miR-25, miR-122, miR-182, miR-18, miR-125,
and miR-32 resulted in a rise in progesterone release,
consistent with the process of luteinization [52]. Further
study identifying the target genes of these miRNA in
ovarian cells is critical in confirming the physiological
function of these miRNAs. In another study, miR-224
was identified as one of 16 transforming growth factor-
b1( T G F - b1) regulated miRNAs in cultured murine
granulosa cells, regulating granulosa cell proliferation
via targeting Smad family member 4 (Smad4) in the
TGF-b1 signal transduction pathway [53].
Our group has recently provided evidence that miR-
378 is expressed in granulosa cells in an inverse manner
compared to the expression of aromatase [54]. In vitro
miR-378 over-expression and knockdown experiments
revealed that aromatase expression, and therefore estra-
diol production, by granulosa cells, is post-transcription-
ally down-regulated by miR-378. Furthermore, site-
directed mutation studies identified two binding sites in
the 3’ untranslated region (UTR) of the aromatase cod-
ing sequence that are critical for the action of miR-378.
We also provided further support for the mechanism of
action by over-expressing the aromatase 3’UTR alone
which resulted in the binding of miR-378 to the recom-
binant 3’UTR decreasing the opportunity for miR-378 to
bind to the endogenous aromatase 3’UTR, reversing the
repressive effect of miR-378 on aromatase protein levels
[54].
MicroRNA regulation of apoptosis in granulosa cells
LH induces ovulation and luteinization via its action on
granulosa cells. During the LH induced transition of
granulosa cells to luteal cells, apoptosis must be inhib-
ited to allow for proper formation of a functional corpus
luteum. A previous study has reported 13 miRNAs
which are differentially expressed in murine granulosa
cells before and 4 h after the hCG/LH surge, with miR-
132, miR-212, and miR-21 being the top three highly
up-regulated [46]. Further study by the same group
revealed that when miR-21 expression was decreased to
one twenty-seventh of its basal expression with locked
nucleic acid (LNA-21) oligonucleotide transfection,
apoptosis was induced in granulosa cells [55]. Similar
results were observed in their in vivo study with a miR-
21 inhibitor, although the targets of miR-21 suppressing
apoptosis in granulosa cells are still to be identified [55].
In addition, Ma et al. (2011) investigated the expres-
sion of miR-378 and the interferon gamma receptor 1
(IFNGR1) gene at different luteal stages in bovine non-
r e g r e s s e da n dr e g r e s s e dc o r p u sl u t e u mu s i n gr e a lt i m e
RT-PCR and Western blots analysis [56]. IFNGR1 plays
a role in luteal cell apoptosis and was predicted to be a
target of miR-378 [56]. Real time RT-PCR revealed that
miR-378 expression was stage-dependent, with the high-
est level being detected in the late stages and the lowest
level of expression occurring in the early stage of corpus
luteum (CL) development. Western blot analysis of
IFNGR1 revealed an inverse relationship between miR-
378 and IFNGR1 protein. This data suggests that miR-
378 may function in suppressi n gl u t e a lc e l la p o p t o s i s
through the IFNGR1 gene [56]. It would be of interest
to confirm the regulatory role of miR-378 with a gain
and loss of function study.
Ovarian pathologies and miRNAs as potential biomarkers
Recent studies have identified miRNAs as potential tis-
sue specific biomarkers of disease and may provide a
useful measure in the diagnosis of numerous pathologies
[57]. Iorio et al. (2007), showed that in comparison to
normal ovaries, numerous miRNA showed differential
expression in epithelial ovarian cancer tissue [58]. It was
found in ovarian cancer tissue that the most significantly
over-expressed miRNAs include miR-200a, miR-141,
miR-200c, and miR-200b. The most down-regulated
miRNAs are miR-199a, miR-140, miR-145, and miR-
125b1 [58]. However, the potential application of using
differential expression of miRNA as a biomarker for dis-
ease would require a tissue biopsy.
In more recent studies, the relationship between circu-
lating miRNAs and cancer has been investigated as exo-
somal miRNA have been shown to mirror the miRNA
expression profile of the originating tumor cells [59].
These circulating tumor derived exosomes offer a poten-
tial non-invasive approach, as they do not require tissue
biopsy for the detection of cancer. In a recent study by
Zhou et al. (2011), the relationship between circulating
miRNAs and premature ovarian failure (POF), an ovar-
ian endocrine disorder which can have very serious
implications for reproduction and overall health status,
was investigated [60]. By comparing the miRNA expres-
sion profiles from the serum of POF and normal
women, it was reported that ten miRNAs were up-regu-
lated and two miRNAs were down-regulated in POF
patients [60]. The miRNAs with increased expression
were miR-202, miR-146a, miR-125b-2*, miR-139-3p,
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and miR-126, and the miRNAs with decreased expres-
sion were let-7c and miR-144 [60].
Prospective
MicroRNAs are important regulators of cell fate deter-
mination, differentiation, proliferation, and tissue remo-
delling during development. Through complementary
approaches, increasing evidence supports the important
role of miRNAs in proliferation, apoptosis, and steroido-
genesis within the ovary. However, knowledge of the
underlying networks is still largely unclear. The biology
of miRNAs in the ovary is a research area that is just
starting to be explored. A greater understanding of
these regulatory effects at the molecular level will be the
next key step, and may allow for the potential usefulness
of miRNAs and their inhibitors in control of human fer-
tility, and reproductive disorders. Future studies to iden-
tify the important target genes as well as the use of
animal models to monitor the phenotypic effects may
allow for a more thorough understanding of the role
played by miRNA in ovarian physiology. In addition,
studies identifying the unique expression signature of
miRNAs in certain ovarian pathological conditions such
as polycystic ovarian syndrome, and ovarian cancer
might offer an additional diagnostic tool to assess these
disorders, and eventually provide insight for novel treat-
ments of these diseases.
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